|
Report No. : |
314375 |
|
Report Date : |
31.03.2015 |
IDENTIFICATION DETAILS
|
Name : |
FOZAN PHARMACEUTICAL INDUSTRIES (PVT) LIMITED |
|
|
|
|
Registered Office : |
36-A, Hayatabad Industrial Estate, Jamrud Road, Peshawar |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2000 |
|
|
|
|
Com. Reg. No.: |
0041630 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
|
|
|
|
No. of Employees : |
90 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
PAKISTAN - ECONOMIC OVERVIEW
Decades of internal political
disputes and low levels of foreign investment have led to slow growth and
underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of
output and two-fifths of employment. Textiles account for most of Pakistan's
export earnings, and Pakistan's failure to expand a viable export base for
other manufactures has left the country vulnerable to shifts in world demand.
Official unemployment was 6.6% in 2013, but this fails to capture the true
picture, because much of the economy is informal and underemployment remains
high. Over the past few years, low growth and high inflation, led by a spurt in
food prices, have increased the amount of poverty. As a result of political and
economic instability, the Pakistani rupee has depreciated more than 40% since
2007. The government agreed to an International Monetary Fund Standby
Arrangement in November 2008 in response to a balance of payments crisis.
Although the economy has stabilized since the crisis, it has failed to recover.
Foreign investment has not returned, due to investor concerns related to
governance, energy, security, and a slow-down in the global economy.
Remittances from overseas workers, averaging about $1 billion a month since
March 2011, remain a bright spot for Pakistan. However, after a small current
account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current
account turned to deficit in the following two years, spurred by higher prices
for imported oil and lower prices for exported cotton. Pakistan remains stuck
in a low-income, low-growth trap, with growth averaging about 3.5% per year
from 2008 to 2013. Pakistan must address long standing issues related to
government revenues and energy production in order to spur the amount of
economic growth that will be necessary to employ its growing and rapidly
urbanizing population, more than half of which is under 22. Other long term
challenges include expanding investment in education and healthcare, adapting
to the effects of climate change and natural disasters, and reducing dependence
on foreign donors.
|
Source
: CIA |
FOZAN PHARMACEUTICAL INDUSTRIES (PVT) LIMITED
|
Registered Address & Factory |
|
36-A, Hayatabad Industrial Estate, Jamrud
Road, Peshawar, Pakistan |
|
Tel |
92 (91) 5822236, 5822283 |
|
Fax |
92 (91) 5822283 |
|
Email |
|
a. |
Nature of Business |
Manufacture & Marketing of
Pharmaceutical Products |
|
b. |
Year Established |
2000 |
|
c. |
Registration # |
0041630 |
None
|
Shahid Waheed
Younus Jamil (Chartered Accountants) 19-A, Jamrud
Lane, University Town, Peshawar, Pakistan |
|
Subject Company was established as a Private Limited Company in 2000 |
|
Authorized Capital |
Rs. 10,000,000/-
divided into 100,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 8,000,000/-
divided into 80,000 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Syed Muhammad Ijaz Mr. Syed Muhammad Arshad Mr. Syed Muhammad Naveed |
Pakistani Pakistani Pakistani |
36-A, Hayatabad Industrial Estate, Jamrud
Road, Peshawar 36-A, Hayatabad Industrial Estate, Jamrud
Road, Peshawar 36-A, Hayatabad Industrial Estate, Jamrud
Road, Peshawar |
Business Business Business |
Chief Executive Director Director |
|
Names |
No. of Shares |
|
Mr. Syed Muhammad Ijaz Mr. Syeda Gulnaz Begum Mr. Syed Muhammad Faisal Mr. Syed Muhammad Fahad Mrs. Syeda Mahnoor Mr. Syed Muhammad Saeed Mr. Syed Muhammad Naveed Mrs. Syeda Taiba Bibi Mr. Syed Muhammad Arshad Mrs. Syeda Sarwat Mr. Syed Ahmad Shah Hasani Mr. Syed Muhammad Hasani Mrs. Wasila Hasani Mr. Syed Abdul Malik Hasani Mrs. Syeda Tuba Hasani |
10,000 10,000 6,000 6,000 6,000 6,000 9,000 9,000 4,000 4,000 2,000 2,000 2,000 2,000 2,000 |
A. Subsidiary
None
B. Associated
Companies
(1) Saydon Pharmaceutical Industries, Pakistan.
Manufacture & marketing of Pharmaceutical
Products by its brand names of ALFOZ, ANTHEX, BRUFOZ, CIPROFAZ, CLAZAN,
DICLOFAZ,
DOXAMINE, EBATIN, ESOPRAL, FEGRAN, FLAN,
FOTOCEF, GYZAN, H2-FOZ, HAEMAID, LEVOFAZ, MECAM, MILEX, NF-400, NICAPOZ-FOZ,
NYCO-P, P-FAZ, PANTAFAZ, PEPTIMAX, POFEN, RAZIM, REWELL, SINURINE FORTE,
90
NORTH
ZHEJIANG XIANJU CHARIOTEER PHARMACEUTICALS,
The capacity and production of the company’s
plant is indeterminable as it involves varying processes of manufacture.
|
Year |
In Pak Rupees |
|
2013 |
80,000,000/- (Estimated) |
|
Mainly exist at major cities of Khyber
Pakhtoonkwa Province of Pakistan |
|
(1) Soneri Bank Limited, Pakistan. (2) The Bank of
Khyber, Pakistan. (3 Habib Bank Limited, Pakistan. (4 Bank Alfalah
Limited, Pakistan. |
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
Khyber Pakhtoonkwa Chamber of Commerce & Industry.(KPCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 102.65 |
|
UK Pound |
1 |
Rs. 152.50 |
|
Euro |
1 |
Rs. 110.25 |
Subject Company was established in 2000 and is engaged in manufacture
& marketing of Pharmaceutical Products. Trade relations are reported as fair.
Subject can be considered for normal business dealings at usual trade terms
& conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.63 |
|
|
1 |
Rs.92.94 |
|
Euro |
1 |
Rs.68.06 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation
is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.